Project Details
Project Description
Two lead series of potent and selective peptide inhibitors of the potassium voltage-gated channel Kv1.3, with potential application for the treatment of a range of autoimmune (AI) diseases. Kv1.3 is a driver of AI disease, and selectively blocking Kv1.3 is gaining recognition as a new immunotherapeutic approach for AI diseases.
| Status | Finished |
|---|---|
| Effective start/end date | 23/10/18 → 23/10/19 |